Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Icosavax, a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Seattle, Washington, specializes in developing innovative vaccines. The company's primary focus is on creating a new type of vaccine designed to protect vulnerable older adults from multiple respiratory viruses using virus-like particles (VLPs). This unique approach has positioned Icosavax as a potential player in the vaccine industry.
Since its inception, Icosavax has made significant strides in vaccine development, attracting attention from investors and industry experts. The company has successfully raised approximately $161 million in funding, demonstrating strong financial backing for its research and development efforts.
In a significant turn of events, Icosavax was acquired by AstraZeneca in February 2024 at a valuation between $838 million and $1.1 billion. This acquisition marks a major milestone for the company and potentially changes its trajectory in terms of future public offerings.
Given the recent acquisition by AstraZeneca, the prospects of an Icosavax IPO are currently uncertain. As a subsidiary of a larger pharmaceutical company, Icosavax's future plans regarding public offerings may have changed. Investors interested in Icosavax stock or looking to buy Icosavax shares should keep in mind that the company's status as a publicly traded entity is now subject to AstraZeneca's corporate strategy.
It's important to note that we do not have any current information or reports about Icosavax's IPO prospects. The acquisition by AstraZeneca has likely altered any previous plans or considerations for going public. As always, potential investors should conduct thorough research and consider seeking professional financial advice before making investment decisions.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Icosavax's IPO prospects remain uncertain, investors eager to explore opportunities in the innovative vaccine development space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotechnology and pharmaceutical sectors, including companies developing cutting-edge vaccine technologies, with lower minimum investments than traditional private equity opportunities.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
